• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Degarelix (degarelix for injection)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Degarelix (degarelix for injection)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Degarelix is a Gonadotropin-releasing hormone (GnRH) receptor antagonist. It binds reversibly to the pituitary GnRH receptors, thereby reducing the release of gonadotropins and consequently testosterone.

    Degarelix is specifically indicated for the treatment of advanced prostate cancer.

    Degarelix is supplied as a powder to be reconstituted with sterile water for subcutaneous administration in the abdomen. The recommended initial dose of the drug is 240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL. The recommended maintenance dose of Degarelix is 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL, every 28 days.

    Clinical Results

    FDA Approval
    FDA approval of Degarelix was based on the results of a clinical trial. This open-label, multi-center, randomized, parallel-group study enrolled 620 subjects with prostate cancer. The subjects received one of two Degarelix dosing regimens or leuprolide for one year: Group A) Degarelix at a starting dose of 240 mg (40 mg/mL) followed by monthly doses of 160 mg (40 mg/mL) subcutaneously; Group B) Degarelix at a starting dose of 240 mg (40 mg/mL) followed by monthly doses of 80 mg (20 mg/mL) subcutaneously; or Group C) leuprolide 7.5 mg intramuscularly monthly. The primary objective was to demonstrate that Degarelix is effective with respect to achieving and maintaining testosterone suppression to castration levels (T < 50 ng/dL), during 12 months treatment. In Group A (240/160 mg) there were 199 responders and the castration rate was 98.3%; in Group B (240/80 mg) there were 202 responders and the castration rate was 97.2%; and in Group C (leuprolide 7.5 mg) there were 194 responders and the castration rate was 96.4%.

    Ongoing Study Commitments

    • Ferring has agreed to complete the ongoing extension study FE200486 CS21A entitled “An Open-Label, Multi-Center, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therapy".
      Protocol Submission: January 2007
      Trial Start Date: March 2007
      First Annual Report Submission: March 2009
      Second Annual Report Submission: March 2010
      Third Annual Report Submission: March 2011
      Final Report and Dataset Submission: June 2012

    Side Effects

    Adverse events associated with the use of Degarelix may include, but are not limited to, the following:
    • hot flashes
    • injection site reactions
    • weight gain
    • increase in liver enzymes
    • tiredness
    • hypertension
    • back and joint pain
    • chills
    • urinary tract infection
    • decreased sex drive and trouble with erectile function

    Mechanism of Action

    Degarelix is a Gonadotropin-releasing hormone (GnRH) receptor antagonist. It binds reversibly to the pituitary GnRH receptors, thereby reducing the release of gonadotropins and consequently testosterone.

    Literature References

    Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU International 2008 Dec;102(11):1531-8

    Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK; Degarelix Study Group A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. The Journal of Urology 2008 Nov;180(5):1986-92

    Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Kold Olesen T Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. European Urology 2008 Oct;54(4):805-13

    Princivalle M, Broqua P, White R, Meyer J, Mayer G, Elliott L, Bjarnason K, Haigh R, Yea C Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. The Journal of Pharmacology and Experimental Therapeutics 2007 Mar;320(3):1113-8

    Broqua P, Riviere PJ, Conn PM, Rivier JE, Aubert ML, Junien JL Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. The Journal of Pharmacology and Experimental Therapeutics 2002 Apr;301(1):95-102

    Additional Information

    For additional information regarding Degarelix or prostate cancer, please visit the Degarelix web page.
    Company Name: Ferring Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing